

KEY REFERENCES

Updated October 2024

5-Year Protocol T

[Glassman AR, Wells JA 3rd, Josic K, Maguire MG, Antoszyk AN, Baker C, Beaulieu WT, Elman MJ, Jampol LM, Sun JK. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema \(Protocol T Extension Study\). *Ophthalmology*. 2020 Sep;127\(9\):1201-1210. doi: 10.1016/j.optha.2020.03.021. Epub 2020 Mar 29. PMID: 32402554; PMCID: PMC7483366.](#)

Protocol T

[Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med*. 2015;372\(13\): 1193–1203.](#)

ASRD 2024 Study

[Dang S, Parke DW, Sodhi GS, Eichenbaum D, Nielsen J, Danzig C, Lalwani G, Moinfar N, London N, Kimura A, Jumper JM, Lord K, Sheth V, Pieramici D, Orlin A, Madson A, Horton M, Blim J, Cao JA, Thompson J, Khanna S, Wykoff CC, Shah AR. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. *JAMA Ophthalmol*. 2024 Aug 1;142\(8\):716-721. doi: 10.1001/jamaophthalmol.2024.2217. PMID: 38935350; PMCID: PMC11211988.](#)

AAO Preferred Practice Pattern RVO

[Flaxel, Christina J. et al. Retinal Vein Occlusions Preferred Practice Pattern®. *Ophthalmology*, Volume 127, Issue 2, P288 - P320.](#)

AAO Preferred Practice Pattern DR

[Flaxel, Christina J. et al. Diabetic Retinopathy Preferred Practice Pattern®. *Ophthalmology*, Volume 127, Issue 1, P66 - P145.](#)

AAO Preferred Practice Pattern AMD

[Flaxel, Christina J. et al. Age-Related Macular Degeneration Preferred Practice Pattern®. *Ophthalmology*, Volume 127, Issue 1, P1 - P65.](#)

**AAO ROP Recommendations**

[Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. *Pediatrics*. 2013 Jan;131\(1\):189-95. doi: 10.1542/peds.2012-2996. Epub 2012 Dec 31. PMID: 23277315.](#)

AAO Biosimilars

https://eyewiki.org/Biosimilars_in_Ophthalmology

NIH Supplement for AMD

[Supplements slow disease progression during late stage of “dry” age-related macular degeneration: New analysis shows benefit of taking AREDS2 formula in late AMD. 2024 Jul.](#)